In the advanced NSCLC EGFR-TKI resistant setting, the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. pemetrexed or docetaxel in patients with tumors with activating EGFR mutations (www.clinicaltrials.gov: NCT016461250). This evidence concerns the gene EGFR and non-small cell lung carcinoma.